ESC 365 - Relation of Nonsteroidal Anti-Inflammatory Drugs and Time in Therapeutic Range in Bleeding Risk in Atrial Fibrillation: the SPORTIF Trials

EHRA Premium Access

Relation of Nonsteroidal Anti-Inflammatory Drugs and Time in Therapeutic Range in Bleeding Risk in Atrial Fibrillation: the SPORTIF Trials

Session: Managing the thromboembolic risk in atrial fibrillation

Topic: Atrial Fibrillation - Stroke Prevention - Oral Anticoagulation

Speaker: Associate Professor M. Proietti (Milan, IT)

Event: EHRA 2018

Congress Presentation

Add to my library

About the speaker

Associate Professor Marco Proietti

University of Milan, Milan (Italy)

11 presentations

1 follower

6 more presentations in this session

Incidence of atrial arrhythmia and uptake of anticoagulation in stroke and non-stroke populations according to arrhythmia burden; a 7-year experience.

Speaker: Doctor P. Chousou (Cambridge, GB)

Incidence and predictors of left atrial appendage thrombus in patients treated with direct oral anticoagulants versus warfarin for non-valvular atrial fibrillation

Speaker: Doctor K. Minami (Utsunomiya, JP)

Left atrial stunning as a predictor of atrial fibrillation occurrence after cryptogenic stroke

Speaker: Doctor J. Farinha (Setubal, PT)

Indications for and outcome in patients undergoing left atrial appendage closure - Results of the Austrian LAAC Registry

Speaker: Mr D. Zweiker (Vienna, AT)

Differences in anticoagulation strategy and outcome in patients with atrial fibrillation according to renal function

Access the full session

Managing the thromboembolic risk in atrial fibrillation

Speakers: Associate Professor M. Proietti, Doctor P. Chousou, Doctor K. Minami, Doctor J. Farinha, Mr D. Zweiker

About the event

EHRA 2018

18 March - 20 March 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources